GlassScriptPhysician profile
Priya Ravindra Patel
NPI 1205098597
$3,154.92
in general payments reported to CMS, 2019-2025
29 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $682 · 2021: $325 · 2022: $885 · 2023: $238 · 2024: $263 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,500.00 | 2019-2022 | |
| Abbvie INC. | $334.11 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $259.56 | 2020-2023 | Xarelto |
| Davol INC. | $162.68 | 2025 | Phasix Mesh |
| Evofem Biosciences, INC. | $92.82 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $74.87 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.82 | 2021-2022 | |
| Avion Pharmaceuticals | $67.41 | 2022-2023 | Balcoltra |
| Exeltis, USA INC. | $67.22 | 2019-2024 | Slynd |
| Agile Therapeutics, INC. | $59.28 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $51.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $48.27 | 2024 | Gardasil, Gardasil 9 |
| Pfizer INC. | $47.98 | 2023-2024 | |
| Organon LLC | $36.40 | 2024 | |
| Sumitomo Pharma America, INC. | $31.07 | 2023-2024 | Myfembree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $26.08 | 2022 | |
| Medtronic, INC. | $23.10 | 2024 | Truclear |
| Eclipse Technology Solutions INC. | $22.00 | 2022 | |
| Astellas Pharma US INC | $19.92 | 2024 | Veozah |
| Dexcom, INC. | $18.74 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $18.44 | 2019 | |
| Tris Pharma INC | $18.08 | 2025 | Dyanavel Xr |
| Amgen INC. | $16.84 | 2025 | Tezspire |
| Hologic Sales and Service, LLC | $16.15 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $15.86 | 2023 | Vivjoa |
| Qol Medical, LLC | $14.52 | 2022 | |
| Lupin INC. | $14.05 | 2020 | |
| Duchesnay USA Incorporated | $12.47 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.